We studied the efficacy and safety of intravenous ondansetron 4 mg for the prevention of postoperative nausea and vomiting after minor gynaecologicallaparoscopic surgery in Oriental women. This double-blind randomised study compared ondansetron with placebo, given before the induction of anaesthesia. The anaesthetic technique used thiopentone, fentanyl, atracurium, nitrous oxide and isojlurane. Patients were studied for 24 h with nausea assessed using a verbal numeric scale from 0-10 and emetic episodes recorded as they occurred.
Postoperative nausea and vomitIng (PONV) are common distressing complications of anaesthesia. 1 , Drug therapy has not been completely effective in preventing or treating PONY and the available antiemetic drugs have associated antihistaminic, anticholinergic or antidopaminergic side-effects. Ondansetron is a highly selective 5-HT3 antagonist which has been very effective in treating vomiting after chemotherapy and radiotherapY,4 and has a side-effect profile no different from placebo. The first published studies of ondansetron in anaesthesia used two oral doses of ondansetron 16 mg for the prophylaxis of PONY' or a single IV dose of ondansetron 8 mg for the treatment of PONY. '.7 Subsequent multi-centre studies have studied ondansetron in various dosages up to 48 mg over 24 h. '" However, the current recommended IV dose for the prophylaxis of PONY is ondansetron 4 mg, based on multi-centre dose ranging studies. '2 There have been no single centre studies assessing the efficacy of this reduced dose for PONY and no such studies in Asian populations.
The objective of this study was to assess the efficacy and safety of ondansetron 4 mg IV for the prophylaxis of nausea and vomiting after gynaecological laparoscopic surgery.
MATERIALS AND METHODS
A double-blind randomised controlled trial was carried out in 210 ASA I or 11 Oriental female patients undergoing laparoscopic sterilisation or diagnostic laparoscopy. The study was approved by the local ethical committee and all patients gave written informed consent. Patients were excluded if they had preexisting nausea or vomiting or had received antiemetic or opioid drugs in the 24 h before surgery. Pregnant patients and those with a history of gastro-oesophageal reflux were also excluded.
Patients were asked for any history of PONY, history of motion sickness and for the day of the current menstrual cycle. Routine urine analysis, full blood count and renal and liver function tests were performed.
No premedication was given and patients were fasted from midnight before surgery. Patients were ran-Ananrhesia al/d /f1fen.sive Care, h)/. 22, 1"10. 2. April, 1994 domised to receive either ondansetron 4 mg (made up to 10 ml with normal saline) or placebo (normal saline 10 ml) given IV over 5 seconds before induction of anaesthesia. Study drugs were prepared by an investigator who was not administering the anaesthetic or making the postoperative assessment. Any sideeffects such as pain on injection, erythema or dizziness were noted. Arterial pressure and heart rate were recorded noninvasively (Dinamap 1846X, Critikon) before, and at 1 and 2 minutes after the injection of the study drug. No intravenous fluids were given.
Anaesthesia was induced with fentanyl 2JLg/kg, thiopentone 4 to 5 mg/kg and atracurium 0.5 mg/kg. Manual ventilation with a facemask was performed for two minutes before the trachea was intubated. Anaesthesia was maintained with nitrous oxide 70070 and isoflurane 0.5070 in oxygen and the ventilation was adjusted to maintain a PE'C02 between 4.5 and 5.0 kPa. At the end of surgery, nitrous oxide and isoflurane were discontinued, the total anaesthetic time was recorded and neostigmine 2.5 mg and atropine 1.2 mg were given to antagonise neuromuscular block. The subsequent time taken for the patient to respond to verbal command was recorded as the recovery time.
All patients stayed in the recovery room for one hour and a record of the incidence and timing of all emetic episodes (retching or vomiting) was kept. Retching or vomiting separated by at least one minute were considered separate episodes. Nausea was graded on an ll-point Verbal Numeric Scale (VNS) (0 = no nausea, 10 = worst nausea ever experienced) on arrival in the recovery room, at 30 min. and at 60 min. after which time the patient was returned to the ward. A record was kept of subsequent emetic episodes.
A rescue antiemetic was given if there were two or more emetic episodes, nausea persisted for 10 min. or the patient requested such medication. In the recovery room, ondansetron 4 mg IV was chosen as the first rescue antemetic, with a second rescue antiemetic, prochlorperazine 12.5 mg IM available if symptoms persisted for another 10 minutes. Pethidine (50 mg IM prn) was prescribed for pain in the postoperative period and prochlorperazine (12.5 mg IM prn) for nausea and vomiting.
Patients were followed up at 5 and 24 h. Nausea was assessed by VNS, emetic episodes were noted and concomitant medications recorded. The preoperative laboratory tests were repeated at 24 h. Patients were questioned directly for any symptoms or adverse events.
Demographic and anaesthetic data were compared between groups using Student's t-test. The paired t-test was used to compare haemodynamic data before and after injection of study drug. Nausea and vomiting were compared between groups at four different time intervals after surgery: 0-1 h. being the time in the recovery room, 1-5 h. being the first four hours after return to the ward and after which patients may potentially have been discharged had they been day stay cases, 5-24 h. and the whole 0-24 h. period. Nausea was analysed both as an ordinal variable (VNS) and as categorical data (nausea or no nausea). The three nausea VNS scores obtained in the recovery room (arrival, 30 and 60 min.) were summed to give an indication of the severity and duration of nausea. The Mann-Whitney test was used to compare the nausea VNS and summed nausea scores. A complete antiemetic response was defined as no nausea and no emetic episode for the 24 h. after the operation. Categorical data were compared using the Chi Square test or Fisher's exact test if the data were in a 2x2 table. P < 0.05 was considered significant.
RESULTS
Six patients were excluded because laparotomy was performed and 102 patients remained in each group. Demographic and anaesthetic data were similar between groups (Table 1) . Laparoscopic sterilisation was performed in 60 patients in the ondansetron group and 61 in the placebo group. The remaining operations were all diagnostic laparoscopy.
No adverse events were noted on injection of ondansetron and no change in arterial pressure or heart rate was seen. Anaesthetic and recovery times were similar between groups (Table 1) . For each time period after surgery, patients in the ondansetron group had fewer emetic episodes compared with the placebo group (Figure 1, P<O.Ol) . The incidence of nausea was reduced in the ondansetron group over the whole 24 h. period, but the difference was small and not significantly different when the 24 h. period was subdivided ( Figure 2 ). However, for the first hour in the recovery room, the summed nauseas score was lower in the ondansetron group, median (range) = 1.6 (0-20), compared with the placebo group, 3.1 (0-26), P<0.05. There were 24 patients with a history of previous PONY and 27 with a history of motion sickness. Patients with a history of previous PONY did not appear to have an increase in PONY although the numbers were small. However, patients with motion sickness were more likely to have nausea (52070) in the four hours after returning to the ward than patients without motion sickness (25070), P<O.OI. The week and phase of the menstrual cycle were distributed evenly throughout both groups and did not affect the incidence of PONY.
Patients undergoing laparoscopic sterilisation had a higher incidence of PONY during the first five postoperative hours (62070) compared with those having diagnostic laparoscopy (42070), P<0.05. A contributing factor could be the greater incidence of postoperative opioid analgesia after laparoscopic sterilisation (37070) than after diagnostic laparoscopy (14070), P< 0.01.
Sixty-two patients received pethidine postoperatively but 16 had PONY before drug administration so that only 46 patients may be considered to have opioid drugs as a contributing factor to PONY. Ondansetron was effective in reducing the incidence of PONY in both the pethidine (9/23) and no pethidine (40/79) subgroups compared with placebo (20/23, P < 0.01) and 55/79, P < 0.05) respectively.
No adverse events were reported and postoperative blood test results showed no significant variations from preoperative values.
DISCUSSION
Ondansetron 4 mg IV was better than placebo for the prophylaxis of PONY in patients undergoing laparoscopic sterilisation or diagnostic laparoscopy. The incidence of PONY in placebo and ondansetron groups was similar to that reported in other studies. '.H"
There are many factors which may influence PONY and a logistic regression analysis has identified gender, history of previous postoperative sickness, postoperative opioids and history of motion sickness as the most important patient factors predicting postoperative sickness. 13 We also found postoperative opioids and history of motion sickness to be associated with an increased incidence of PONY.
The phase of the menstrual cycle has been associated with an increase of PONY but evidence is conflicting. Honkavaara et at. 14 found the highest incidence of PONY during the luteal phase (days 20-24) and the lowest before and during menstruation (days 25-6) while Beattie et at. 15 found the greatest incidence of PONY during menstruation (days 1-8). In patients taking the oral contraceptive pill, McDonald et at. 16 found that the greatest incidence of PONY was during days 9-15.
We observed no adverse effects following the rapid administration of ondansetron and now no longer dilute the drug before injection. Other workers have also reported cardiovascular stability after intravenous ondansetron. 17 Although ondansetron was superior to placebo, comparative studies are necessary. One study concluded that ondansetron 8 mg was superior to metoclopramide 10 mg or droperidol 1.25 mg even though sample sizes were small with 22 patients in each group. 18 A subsequent abstract from the same group reported that ondansetron 4 mg was inferior to droperidol1.25 mg. 19 Other recent abstracts have also found no clearcut superiority for ondansetron. 2023
Ondansetron is considerably more expensive than other antiemetics and it is important to assess the costbenefits of new treatments. A preliminary report from the United Kingdom estimated that the average cost associated with PONY was £3.38 for every inpatient having major gynaecological surgery. 24 Most studies with ondansetron have concentrated on gynaecological patients. Other patient populations have a lower incidence of PONY and the efficacy and cost-benefit considerations of ondansetron will be different.
Ondansetron failed to prevent PONY in 48070 of patients and this is far from ideal. The aetiology of PONY is multifactorial, unlike chemotherapy-induced nausea and vomiting, so one cannot expect the same efficacy in PONY as that seen in chemotherapy. Ondansetron has a very specific 5-HT3 antagonist action and should not be effective when PONY is caused by other mechanisms. For example, ondansetron is not an effective drug for motion sickness. 4 It is logical to infer that combinations of anti emetic drugs with different modes of action may be more effective than single drug therapy. Such combinations have been used successfully in chemotherapy but have not been explored in PONV. 3 After the initial dose of antiemetic drug, the best treatment for patients continuing to have PONY is uncertain. Ondansetron has been shown to be effective for the treatment of PONV"·7.25 but 12 of our 18 patients who received rescue ondansetron in the recovery room continued to have symptoms in the next 4 h. on the ward. In the ten patients from the placebo group, ondansetron 4 mg may not have been a sufficient dose. In the eight patients in whom prophylactic ondansetron 4 mg had already failed, an additional 4 mg did not appear to be completely successful. The number of patients in these subgroups was small so that we can draw no conclusions. We would favour a different antiemetic with different mode of action rather than an additional dose of the same antiemetic.
Patients receiving opioid drugs had a higher incidence of PONY and, given the multifactorial nature of PONY, it should be possible to reduce PONY by other techniques apart from using antiemetic drugs. The use of propofol for anaesthesia and non-steroidal anti-inflammatory drugs and local anaesthetics for analgesia will help to reduce the incidence of PONY. 3 Although we found ondansetron to be effective and safe, the best and most cost-effective techniques for preventing PONY have yet to be determined.
